

WEDNESDAY 21st MARCH 2012 COMMENCING 10.30 AM
(UNTIL 4.00 PM APPROX)
AT CARDIFF METROPOLITAN UNIVERSITY, LLANDAFF
CAMPUS, WESTERN AVENUE, CARDIFF CF5 2YB

AGENDA

- | | |
|---|-----------------------------------|
| 1. Welcome and introduction | Enclosure |
| 2. Apologies | |
| 3. Declarations of interest | |
| 4. Chairman's report (verbal update) | |
| 5. Minutes of previous meeting | 1/AWMSG/0312 |
| 6. Appraisal 1
Esomeprazole (Nexium® IV) for gastric antisecretory treatment when the oral route is not possible, such as gastro-oesophageal reflux disease (GORD) in patients with erosive reflux oesophagitis and/or severe symptoms of reflux for children and adolescents aged 1-18 years of age. | 2/AWMSG/0312
Appendices |
| 7. Appraisal 2
Adalimumab (Humira®▼) in combination with methotrexate for the treatment of active polyarticular juvenile idiopathic arthritis, in children and adolescents aged 4 to 17 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs. Adalimumab can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. | 3/AWMSG/0312
Appendices |
| 8. Update from All Wales Prescribing Advisory Group | 4/AWMSG/0312 |
| 9. CEPP National Audit: Patient safety – lithium prescribing | 5/AWMSG/0312 |
| 10. CEPP National Audit: - Towards more appropriate management of depression in a primary care setting | 6/AWMSG/0312 |
| 11. Guidance on prescribing for erectile dysfunction | 7/AWMSG/0312 |
| 12. Date of next meeting - Wednesday, 9th May 2012 in Abergavenny | |